Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program

Core Viewpoint - Quantum BioPharma Ltd. has engaged MZHCI, LLC to enhance its investor relations and financial communications strategy, focusing on increasing visibility in the investment community and promoting its innovative product pipeline targeting brain disorders and alcohol health [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company dedicated to developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [11]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [11]. Strategic Engagement - MZ will collaborate with Quantum BioPharma's management to create a comprehensive capital markets strategy to boost the company's visibility [2]. - The engagement with MZ is for an initial period of two months at a cost of $10,000 per month, with the option for automatic renewal [8]. Product Focus - Quantum BioPharma is developing products like unbuzzd™ and rekvry™, which utilize innovative technology to address excessive alcohol use, a significant public health issue [3]. - The company is also targeting demyelinating diseases, with multiple sclerosis affecting nearly 1 million people in the U.S. and 2.8 million globally [4]. Revenue Potential - The company sees substantial revenue potential in its focus areas, particularly in addressing unmet needs in brain disorders and alcohol health [5]. - Quantum BioPharma retains a 25.71$250 million, after which the royalty will decrease to 3% [11].